- Home
- LNN vs AUPH Comparison
LNN vs AUPH Comparison
Compare LNN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNN
- AUPH
- Stock Information
- Founded
- LNN 1954
- AUPH 1993
- Country
- LNN United States
- AUPH Canada
- Employees
- LNN N/A
- AUPH N/A
- Industry
- LNN Industrial Machinery/Components
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- LNN Industrials
- AUPH Health Care
- Exchange
- LNN Nasdaq
- AUPH Nasdaq
- Market Cap
- LNN 1.5B
- AUPH 1.4B
- IPO Year
- LNN 1988
- AUPH 1999
- Fundamental
- Price
- LNN $140.46
- AUPH $12.11
- Analyst Decision
- LNN Hold
- AUPH Strong Buy
- Analyst Count
- LNN 1
- AUPH 4
- Target Price
- LNN $136.00
- AUPH $12.25
- AVG Volume (30 Days)
- LNN 76.8K
- AUPH 2.8M
- Earning Date
- LNN 10-23-2025
- AUPH 07-31-2025
- Dividend Yield
- LNN 1.03%
- AUPH N/A
- EPS Growth
- LNN 5.71
- AUPH N/A
- EPS
- LNN 6.96
- AUPH 0.42
- Revenue
- LNN $677,807,000.00
- AUPH $260,111,000.00
- Revenue This Year
- LNN $13.09
- AUPH $12.15
- Revenue Next Year
- LNN N/A
- AUPH $18.34
- P/E Ratio
- LNN $20.17
- AUPH $28.76
- Revenue Growth
- LNN 9.46
- AUPH 25.59
- 52 Week Low
- LNN $112.14
- AUPH $6.42
- 52 Week High
- LNN $150.96
- AUPH $12.53
- Technical
- Relative Strength Index (RSI)
- LNN 53.46
- AUPH 70.10
- Support Level
- LNN $137.32
- AUPH $11.83
- Resistance Level
- LNN $143.81
- AUPH $12.46
- Average True Range (ATR)
- LNN 2.90
- AUPH 0.41
- MACD
- LNN 0.19
- AUPH -0.07
- Stochastic Oscillator
- LNN 61.54
- AUPH 68.89
About LNN Lindsay Corporation
Lindsay Corp provides various proprietary water management and road infrastructure products and services. It has operations categorized into two main reporting segments: Irrigation, and Infrastructure. The company generates maximum revenue from the Irrigation segment. Its Irrigation segment includes manufacturing and marketing center pivot, lateral move, and hose reel irrigation systems, as well as various technology solutions such as GPS positioning and guidance, variable rate irrigation, wireless irrigation management, M2M communication technology, and smartphone applications. Geographically, it derives a majority of its revenue from the United States.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.